Evrópusambandið - enska - EMA (European Medicines Agency)

accord healthcare s.l.u. - dasatinib - precursor cell lymphoblastic leukemia-lymphoma; leukemia, myelogenous, chronic, bcr-abl positive - antineoplastic agents - dasatinib accordpharma is indicated for the treatment of adult patients with: newly diagnosed philadelphia chromosome positive (ph+) chronic myelogenous leukaemia (cml) in the chronic phase. chronic, accelerated or blast phase cml with resistance or intolerance to prior therapy including imatinib. ph+ acute lymphoblastic leukaemia (all) and lymphoid blast cml with resistance or intolerance to prior therapy.dasatinib accordpharma is indicated for the treatment of paediatric patients with: newly diagnosed ph+ cml in chronic phase (ph+ cml-cp) or ph+ cml-cp resistant or intolerant to prior therapy including imatinib. newly diagnosed ph+ all in combination with chemotherapy.

Ástralía - enska - Department of Health (Therapeutic Goods Administration)

dr reddys laboratories australia pty ltd - dasatinib propylene glycol, quantity: 58 mg (equivalent: dasatinib, qty 50 mg) - tablet, film coated - excipient ingredients: triacetin; croscarmellose sodium; lactose; titanium dioxide; hydrogenated castor oil; silicon dioxide; microcrystalline cellulose; hypromellose; magnesium stearate - dasatinib-drla is indicated for the treatment of adults aged 18 years or over with:,- newly diagnosed philadelphia chromosome positive acute lymphoblastic leukaemia integrated with chemotherapy. - philadelphia chromosome positive acute lymphoblastic leukaemia with resistance or intolerance to prior therapy.,dasatinib-drla is indicated for the treatment of paediatric patients with:,- newly diagnosed ph+ all in combination with chemotherapy.

Ástralía - enska - Department of Health (Therapeutic Goods Administration)

dr reddys laboratories australia pty ltd - dasatinib propylene glycol, quantity: 116 mg (equivalent: dasatinib, qty 100 mg) - tablet, film coated - excipient ingredients: microcrystalline cellulose; hypromellose; silicon dioxide; lactose; titanium dioxide; croscarmellose sodium; magnesium stearate; triacetin; hydrogenated castor oil - dasatinib-drla is indicated for the treatment of adults aged 18 years or over with:,- newly diagnosed philadelphia chromosome positive acute lymphoblastic leukaemia integrated with chemotherapy. - philadelphia chromosome positive acute lymphoblastic leukaemia with resistance or intolerance to prior therapy.,dasatinib-drla is indicated for the treatment of paediatric patients with:,- newly diagnosed ph+ all in combination with chemotherapy.

Kanada - enska - Health Canada

apotex inc - dasatinib - tablet - 20mg - dasatinib 20mg - antineoplastic agents

Kanada - enska - Health Canada

apotex inc - dasatinib - tablet - 50mg - dasatinib 50mg - antineoplastic agents

Kanada - enska - Health Canada

apotex inc - dasatinib - tablet - 100mg - dasatinib 100mg - antineoplastic agents

Kanada - enska - Health Canada

apotex inc - dasatinib - tablet - 70mg - dasatinib 70mg - antineoplastic agents

Kanada - enska - Health Canada

apotex inc - dasatinib - tablet - 80mg - dasatinib 80mg - antineoplastic agents

Kanada - enska - Health Canada

taro pharmaceuticals inc - dasatinib - tablet - 20mg - dasatinib 20mg - antineoplastic agents

Kanada - enska - Health Canada

taro pharmaceuticals inc - dasatinib - tablet - 50mg - dasatinib 50mg - antineoplastic agents